Launch price: from €29.90 per box. Free delivery from 2 boxes.
bisphosphonate
Strengthens bone and reduces the risk of fracture. This molecule appears in 207 of the medicines we have indexed.
We do not make a formula for this treatment. Talk to your doctor or pharmacist about these active ingredients.
See the detailsBy the Layer Nutrition editorial teamHow the atlas classifies the 664 molecules
This molecule belongs to the “bisphosphonate (osteoporosis)” category. This medicine strengthens the solidity of the bone and reduces the risk of fracture.
In practice: Strengthens bone and reduces the risk of fracture. It is most often a long-term treatment, taken at regular times over long periods; its benefit is judged over time, not by how you feel on a given day.
These names come from the public registers of 32 countries: the ANSM for France, the AEMPS for Spain, the AIFA for Italy, the HPRA for Ireland, Swissmedic for Switzerland, and the European Medicines Agency for the others.
Most widespread
No name matches.
The atlas gives each molecule one of these three answers. Most call for nothing.
Risedronate only protects bone if calcium and vitamin D are not lacking. These two intakes form the foundation on which the treatment acts, and food makes it possible to secure them every day, in addition to your treatment.
Calcium is found first in dairy products, yoghurt and cheese, then in canned sardines and salmon eaten with their bones. Kale and broccoli also provide a good share of it. The calcium in spinach is an exception: it is poorly absorbed, because it remains bound to oxalic acid.
Vitamin D is rare on the plate. Oily fish, salmon, sardine and mackerel, are among the only notable natural sources, alongside egg yolk and mushrooms exposed to UV. Since the tablet is taken on an empty stomach, a food or supplement rich in calcium is placed at another time of day, well apart from the dose.
Risedronate belongs to the family of nitrogen-containing bisphosphonates. Once bound to bone, it inhibits an enzyme, farnesyl pyrophosphate synthase, which holds a key position in the mevalonate pathway. By blocking this enzyme, it prevents the prenylation of the small GTPases that the osteoclast, the cell responsible for breaking down bone, needs in order to function. Deprived of these proteins, the osteoclast detaches from the bone surface and stops resorbing bone.
Risedronate has a strong affinity for the hydroxyapatite crystals that form the mineral framework of bone. It accumulates there and acts as an antiresorptive agent: at the cellular level, it inhibits osteoclasts. By slowing bone breakdown, it preserves bone mineral density and reduces the fragility that leaves people exposed to fractures.
Risedronate is indicated for osteoporosis in postmenopausal women and in men, as well as for corticosteroid-induced osteoporosis, the kind that accompanies prolonged corticosteroid treatment. It is also prescribed for Paget’s disease, a condition in which bone remodeling runs out of control. The common thread across these indications remains the same: to strengthen bone and reduce the risk of fracture.
In people with osteoporosis, risedronate reduces the risk of vertebral and non-vertebral fractures by about 40 %. This measured benefit justifies treatment sustained over time, whose effect is judged by the strength of the bone rather than by any immediate sensation.
The tablet is taken on an empty stomach, swallowed whole with a large glass of still water, that is 180 to 240 ml, at least 30 minutes before the first food or drink of the day. After taking it, you must remain standing or seated, without lying down, for at least 30 minutes. These rules have two reasons: food and many beverages reduce the absorption of risedronate, and the upright position limits contact between the tablet and the oesophagus.
The terminal half-life of risedronate is about 561 hours, that is nearly 23 days, in osteopenic postmenopausal women, because the molecule binds durably to bone before being released from it. This persistence does not remove the need for regularity: it is the repeated dose over time that protects the bone. This treatment is not modified or stopped on one’s own initiative, but in agreement with the doctor who prescribed it.
In the phase 3 trials on postmenopausal osteoporosis, with risedronate 5 mg per day versus placebo, the reported effects were at levels close to those of placebo: back pain 28.0 % versus 26.1 %, arthralgia 23.7 % versus 22.1 %, abdominal pain 12.2 % versus 9.9 % and dyspepsia 10.8 % versus 10.6 %. The effect specific to risedronate thus remains close to placebo.
Bisphosphonates also have effects that are specific to them. An oesophagitis and upper digestive disorders have been described, which explain the precautions for taking the drug, along with a flu-like acute-phase reaction occurring within 1 to 3 days after the dose. More rarely, osteonecrosis of the jaw may appear, and atypical femoral fractures have been observed after prolonged use. Any unusual sign should be reported to the doctor.
Hypocalcaemia and other disorders of bone and mineral metabolism must be corrected before starting risedronate. Calcium and vitamin D are also brought back to normal before initiation, and a supplement of 1000 to 1200 mg per day of calcium and 800 to 1000 IU per day of vitamin D is recommended when dietary intake is not sufficient. These two nutrients are the material and the regulator without which the treatment cannot act fully.
Calcium also interacts directly with the medication. Calcium, antacids and products containing divalent cations decrease the absorption of risedronate, and food reduces it by about 30 to 55 % depending on the timing of the dose relative to the meal. This is the reason for taking it on an empty stomach: a calcium supplement is taken at another time of day, well apart from the tablet.
Before starting a bisphosphonate, several parameters are checked: serum calcium, vitamin D and kidney function. This baseline assessment ensures that the body has the necessary minerals and that the kidney will be able to handle the medication.
Monitoring then continues throughout the treatment. It includes measuring height and weight, as well as checking blood calcium. These simple markers make it possible to adjust management and to verify that the treatment is fulfilling its role.
Beyond the plate, a single isolated nutrient can be worth discussing, to confirm with your doctor or pharmacist. Here is which one and in which form.
Calcium is the most abundant mineral in the body, involved in bone health. Calcium citrate is well absorbed, including away from meals, whereas carbonate requires an acidic environment for its absorption.
Preferred formcalcium citrate (does not depend on gastric acidity)
To be confirmed with your doctor or pharmacist.
Vitamin D is a fat-soluble vitamin. The D3 form (cholecalciferol) is the one adopted by most guidelines. It is better absorbed when taken during a meal that contains fats.
Preferred formD3 (cholecalciferol), during a fatty meal
To be confirmed with your doctor or pharmacist.
Type the name written on the box. The atlas gives you its answer.
For example Panadol, Doliprane or paracetamol.
The package leaflet advises taking it on an empty stomach with a large glass of plain water, then staying upright without lying back down for at least 30 minutes, and waiting that same interval before eating, drinking or taking anything else. The exact instructions for your schedule (daily, weekly or monthly) are set out in the leaflet: follow it and confirm with your doctor or pharmacist.
The package leaflet notes in particular digestive problems such as nausea and abdominal pain, as well as headaches. For the full list and what to do, refer to the leaflet in your box and talk to your doctor or pharmacist.
Calcium supplements, antacids and certain medicines can interfere with its absorption if taken at the same time, which is why spacing them out matters. Tell your doctor or pharmacist about all your medicines and supplements, and refer to the leaflet for the precise interactions.
Yes: the package leaflet states that calcium, like antacids, can reduce the absorption of risedronate when taken at the same time, and recommends taking them well apart from each other. The exact timing of each dose is worked out with your doctor or pharmacist based on the leaflet.
In osteoporosis, management guidelines note that an adequate intake of calcium and vitamin D is a foundation to consider alongside treatment, with supplementation considered when diet does not cover the requirements. This is an underlying nutritional issue, distinct from the action of the medicine itself.
The active to consider is vitamin D3 (cholecalciferol), the best-studied form for maintaining an adequate status, paired with a calcium intake, for example as calcium citrate, which is regarded as well tolerated. Diet remains the primary source; a blood test for vitamin D and the decision about any supplementation should be discussed with your doctor, and any calcium intake should be spaced apart from risedronate.
These answers draw on the patient leaflet and on the published literature. For any question about your medicine, the patient leaflet and your doctor or pharmacist are the reference.
We will write to you the day your formula becomes available.